3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
7
Phase 1
2
Phase EARLY_PHASE1
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
cyclopia sequence
6
Prostatic Neoplasms
6
Neoplasm Metastasis
6
Breast Neoplasms
6
Lung Neoplasms
4
Dyspnea
4
Recurrence
3
Primary Myelofibrosis
3
Oropharyngeal Neoplasms
3
Multiple Myeloma
3
Esophageal Neoplasms
3
Carcinoma, Squamous Cell
3
Squamous Cell Carcinoma of Head and Neck
2
Polycythemia Vera
2
Pain
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Thrombocythemia, Essential
1
Splenomegaly
1
Speech
1
Sezary Syndrome
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Plexosarcoma
1
Pathologic Complete Response
1
Interventions
Paclitaxel
134
Carboplatin
129
Bevacizumab
86
Gemcitabine
45
pembrolizumab
37
olaparib
33
Cisplatin
30
liposomal doxorubicin
29
Docetaxel
29
Cyclophosphamide
29
Topotecan
28
niraparib
27
Taxes
20
Etoposide
18
Filgrastim
16
Doxorubicin
16
Immunoglobulin G
15
Disulfides
15
apatinib
12
Letrozole
12
Albumin-Bound Paclitaxel
12
Drug Therapy
11
fluzoparib
10
fludarabine
10
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
Biopsy
10
durvalumab
9
Nivolumab
9
pazopanib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Ovarian Neoplasms
×
Surveys and Questionnaires
×
Clear all
NCT02124421
2024-11-19
CRS/HIPEC
Mercy Medical Center
Phase 2
Active not recruiting
32 enrolled